Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Opdivo
Pharma
BMS' Opdivo widens lung cancer reach with perioperative FDA nod
The PD-1/L1 inhibitor is now cleared to treat certain non-small cell lung cancer patients before and after surgery.
Zoey Becker
Oct 3, 2024 3:54pm
Experts back FDA's plan to restrict PD-1 drugs in GI cancers
Sep 26, 2024 1:38pm
FDA challenges broad use of PD-1 drugs in stomach cancer
Sep 24, 2024 2:30pm
ESMO: GSK's Zejula, pharma&'s Rubraca-Opdivo combo disappoint
Sep 14, 2024 8:45am
With ODAC, FDA weighs limiting PD-1 drugs in stomach cancer
Aug 22, 2024 3:28pm
Amid concerns, FDA approves AZ's Imfinizi in perioperative NSCLC
Aug 16, 2024 10:51am
